Table 2.
Clinical and neurophysiological findings in ulnar and median nerves.
| Clinical impairment | NCS | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nerve | Group | Pc | Sen | T/P | MFT | VMT | SVMR | sNCS | mNCS |
| At diagnosis | |||||||||
| Ulnar | PB | 10% | 10% | 10% | 0% | 0% | 20% | 10% | 30% |
| MB | 67% | 25% | 25% | 0% | 0% | 38% | 67% | 79% | |
| *P | <0.001 | 0.259 | 0.259 | – | – | 0.205 | <0.001 | 0.003 | |
| Median | PB | 10% | 0% | 0% | 0% | 0% | 0% | 15% | 10% |
| MB | 67% | 13% | 13% | 0% | 0% | 29% | 50% | 67% | |
| *P | <0.001 | 0.239 | 0.239 | – | – | 0.011 | 0.034 | <0.001 | |
| Follow-up | |||||||||
| Ulnar | PB | 5% | 0% | 0% | 0% | 0% | 15% | 40% | 50% |
| MB | 21% | 17% | 17% | 4% | 8% | 13% | 75% | 42% | |
| *P | 0.197 | 0.114 | 0.114 | 1.000 | 0.493 | 1.000 | 0.041 | 0.800 | |
| Median | PB | 5% | 0% | 0% | 0% | 0% | 10% | 15% | 35% |
| MB | 21% | 17% | 17% | 0% | 0% | 13% | 67% | 54% | |
| *P | 0.197 | 0.114 | 0.114 | – | – | 1.000 | <0.001 | 0.330 | |
| **P (at diagnosis and follow-up) | |||||||||
| Ulnar | PB | 1.000 | – | – | – | – | 1.000 | 0.980 | 0.157 |
| MB | 0.003 | 0.500 | 0.500 | – | – | 0.031 | 0.660 | 0.014 | |
| Median | PB | 1.000 | – | – | – | – | – | 1.000 | 0.025 |
| MB | 0.003 | 1.000 | 1.000 | – | – | 0.344 | 0.194 | 0.317 | |
Pc, palmar cyanosis; Sen, sensory impairment; PB, paucibacillary; MB, multibacillary; SVMR, skin vasomotor reflex; NCS, nerve conduction study; sNCS, sensory nerve conduction study; mNCS, motor nerve conduction study; T/P, thermal and/or pain impairment; MFT, monofilament test; VMT, voluntary muscle test impairment; –, not done due to 0 values.
*
P value of Fisher's exact test used to compare variables between PB and MB patients;
**
P value of McNemar test used to compare variables at diagnosis and follow-up.